Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2019 09:00 ET | Source: CohBar, Inc.

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
November 06, 2019 16:04 ET | Source: CohBar, Inc.

CohBar Reports Third Quarter 2019 Financial Results and Business Update

MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
November 05, 2019 09:00 ET | Source: CohBar, Inc.

CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity

MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
October 24, 2019 09:00 ET | Source: CohBar, Inc.

CohBar to Announce 2019 Third Quarter Financial Results and Provide Business Update on November 6, 2019

Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing...
October 23, 2019 08:45 ET | Source: CohBar, Inc.

CohBar Expands Board with Biotech Veteran Misha Petkevich

MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and...
October 15, 2019 09:00 ET | Source: CohBar, Inc.

CohBar to Present at the 2019 BIO Investor Forum

MENLO PARK, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases and...
September 18, 2019 09:00 ET | Source: CohBar, Inc.

CohBar to Present at the 2019 Cantor Global Healthcare Conference

MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related diseases...
August 07, 2019 16:05 ET | Source: CohBar, Inc.

CohBar Reports Second Quarter 2019 Financial Results and Business Update

Company to host conference call and webcast today, August 7th, at 5:00 p.m. EDT MENLO PARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology...
July 31, 2019 16:05 ET | Source: CohBar, Inc.

CohBar to Announce 2019 Second Quarter Financial Results and Provide Business Update on August 7, 2019

MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
June 10, 2019 09:00 ET | Source: CohBar, Inc.

CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions

MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company focused on developing mitochondria based therapeutics to treat age-related...